Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC

Exclusion Criteria

• •4. At least one measurable lesion consistent with RECIST v1.1;
• •5. ECOG PS score: 0-1;
• •6. The organ function level is good;
• •1. Untreated (radiation or surgery) central nervous system metastasis, or accompanied by meningeal metastasis, spinal cord compression, etc.;
• •2. Uncontrolled pleural effusion, pericardial effusion, or peritoneal effusion with clinical symptoms;
• •3. Previous or co-existing malignant neoplasms;
• •4. The presence of any active or known autoimmune disease;
• •5. Have clinical symptoms or diseases of the heart that are not well controlled;
• •6. People with past or current interstitial pneumonia/interstitial lung disease;
• •7. Known allergic reactions to any component of SHR-A1921, Adebrelimab, or severe allergic reactions to other monoclonal antibodies;
• •8. Have previously received topoisomerase I inhibitors (including but not limited to irinotecan, Topotecan), TROP-2ADC, or ADC drugs containing topoisomerase I inhibitors; Previously received anti-PD-1 /PD-L1 antibody or anti-CTLA-4 antibody treatment;